Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 4Recruiting 2

Sponsor Class

NIH 3INDUSTRY 2OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 4Sarcoma 1Other hematologic neoplasm 1

Conditions

Lymphoma, B-Cell 2Sarcoma, Ewing 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 415Magnetic Resonance Spectroscopy 332pembrolizumab 261Biopsy 227Carboplatin 216Cisplatin 179Cyclophosphamide 174Paclitaxel 148Nivolumab 135Gemcitabine 130Radiotherapy 120Dexamethasone 105Bevacizumab 101fludarabine 95Radiation 94Fluorouracil 93Pemetrexed 88Doxorubicin 88Docetaxel 83Rituximab 82venetoclax 81durvalumab 81Oxaliplatin 81Leucovorin 76atezolizumab 68Lenalidomide 66Capecitabine 66Prednisone 65Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × etoposide phosphate × 30 days × Clear all
NCT02306161 2026-05-27

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
312 enrolled 14 charts
Sarcoma

Sarcoma, Ewing

NCT05675410 2026-05-27

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT03983824 2026-05-13

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06230224 2026-05-11

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
216 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04663347 2026-05-05

EPCOREâ„¢ NHL-2

Genmab

Phase 1/2 Active not recruiting
543 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡